TRADE POLICY | 2026-07-21

Section 232 Pharmaceutical Tariffs: 100% Duty on Patented Drugs and California Importers

An April 2026 presidential proclamation under Section 232 imposes a 100 percent ad valorem tariff on patented pharmaceuticals, biologics, and their active ingredients, reshaping cost and compliance exposure for California biotech importers moving product through the Ports of Los Angeles and Long Beach.

By Anatolii Trembach, Esq. (California State Bar No. 349304; LL.M., USC Gould School of Law; admitted to the U.S. Court of International Trade), Trembach Law Firm, APC · Published

In April 2026, the President invoked Section 232 of the Trade Expansion Act of 1962 to impose a sweeping tariff on imports of patented, branded pharmaceutical products, biologics, and their active pharmaceutical ingredients. The headline figure is a 100 percent ad valorem duty, applied as the defaul

Contact Trembach Law Firm at (818) 514-7680 for a confidential consultation.

Trembach Law Firm | 27001 Agoura Road, Suite 350, Calabasas, CA 91301